By Yantoultra Ngui and Jasmeen Ara Islam Shaikh Feb 3 (Reuters) - Chinese industrial automation equipment maker Wuxi Lead Intelligent Equipment plans to raise up to HK$4.29 billion ($549 million) in a ...

WuXi Biologics (Cayman) has entered three new alliances with Vertex Pharmaceuticals, Sinorda Biomedicine, and HanchorBio. The partnerships focus on antibody therapeutics for autoimmune diseases and ...

China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...

Two recent, seemingly unrelated corporate maneuvers offer a telling glimpse into the strategic pivots major Chinese companies are making in response to shifting consumer habits and global political ...

Forbes contributors publish independent expert analyses and insights. I am the CIO of KraneShares, a China-focused ETF provider. Asian equities were mixed overnight as Mainland China's STAR Market and ...

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...

HONG KONG, Aug. 19, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.

China-based biologics services group WuXi Biologics (HKG: 2269) has entered a strategic collaboration with Sinorda ...

SYDNEY, Nov 17 (Reuters) - Chinese medical research group WuXi XDC's shares (2268.HK), opens new tab staged one of the strongest trading debuts for an initial public offering in Hong Kong this year on ...